Related Experiment Video
Updated: Jul 26, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Novel Targets, Novel Treatments: The Changing Landscape of Non-Small Cell Lung Cancer
Dorine de Jong1, Jeeban P Das2, Hong Ma3
1Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.
Abstract:
Treatment of non-small cell lung cancer (NSCLC) has undergone a paradigm shift. Once a disease with limited potential therapies, treatment options for patients have exploded with the availability of molecular testing to direct management and targeted therapies to treat tumors with specific driver mutations. New in vitro diagnostics allow for the early and non-invasive detection of disease, and emerging in vivo imaging techniques allow for better detection and monitoring. The development of checkpoint inhibitor immunotherapy has arguably been the biggest advance in lung cancer treatment, given that the vast majority of NSCLC tumors can be treated with these therapies. Specific targeted therapies, including those against KRAS, EGFR, RTK, and others have also improved the outcomes for those individuals bearing an actionable mutation. New and emerging therapies, such as bispecific antibodies, CAR T cell therapy, and molecular targeted radiotherapy, offer promise to patients for whom none of the existing therapies have proved effective. In this review, we provide the most up-to-date survey to our knowledge regarding emerging diagnostic and therapeutic strategies for lung cancer to provide clinicians with a comprehensive reference of the options for treatment available now and those which are soon to come.
Insights
Non-small cell lung cancer (NSCLC) treatment has advanced significantly with molecular testing, targeted therapies, and immunotherapy. Emerging diagnostics and novel treatments like bispecific antibodies offer new hope for patients.
Area of Science:
- Oncology
- Pulmonology
- Molecular Diagnostics
Background:
- Non-small cell lung cancer (NSCLC) treatment has evolved from limited options to a personalized approach.
- Advances in molecular testing and targeted therapies have revolutionized NSCLC management.
- Immunotherapy, particularly checkpoint inhibitors, represents a major breakthrough in NSCLC treatment.
Purpose of the Study:
- To provide an up-to-date review of emerging diagnostic and therapeutic strategies for NSCLC.
- To serve as a comprehensive reference for clinicians on current and future NSCLC treatment options.
Main Methods:
- Review of current literature on NSCLC diagnostics and therapeutics.
- Analysis of advancements in molecular testing, targeted therapies, and immunotherapies.
- Exploration of novel and emerging treatment modalities.
Main Results:
- Molecular testing enables personalized treatment selection for NSCLC patients.
- Targeted therapies (e.g., against KRAS, EGFR, RTK) improve outcomes for patients with actionable mutations.
- Checkpoint inhibitor immunotherapy is effective for a majority of NSCLC tumors.
Conclusions:
- NSCLC treatment has shifted towards precision medicine driven by molecular insights.
- Emerging therapies including bispecific antibodies, CAR T-cell therapy, and molecular targeted radiotherapy show promise for refractory cases.
- Continuous innovation in diagnostics and therapeutics is expanding treatment options for NSCLC patients.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...